TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Oric Pharmaceuticals
ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor

ORIC Pharmaceuticals published research in Cancer Research detailing enozertinib, a highly selective brain-penetrant EGFR inhibitor targeting non-small cell lung cancer mutations, demonstrating potential for treating intracranial disease.

Insights
ORIC   positive

Company published promising preclinical data showing a novel drug's potential to address unmet medical needs in cancer treatment, with a patient case demonstrating complete response in systemic and brain metastases